Tools for Clinical Trials Professionals
Secure, Web-based product warehouses patient health data across multiple sites
Convergence CT (Honolulu, HI) offers an innovative software product that consolidates and manages patient health data for clinical trials and other health care environments. DB*FOCUS separates protected health information and de-identified patient data, encrypts it, and then provides clinical researchers access to the information through a secure, centralized, Web-based management system.
DB*FOCUS
DB*FOCUS tracks all activity into and out of the patient record, either at a single location or across multiple sites. In this case, patient data are multi-encountered and longitudinally linked across all facilities in the clinical study. The security feature offered by the product enhances privacy compliance, including HIPAA.
According to Convergence CT, DB*FOCUS can save costs because its easy installation eliminates the need for a full-time database administrator, plus it also reduces organizational inefficiencies and optimizes resource utilization.
Convergence CT, (808) 536-3040, www.convergencect.com
Replace medication diaries and pill counts with this automatic compliance system
Information Mediary Corporation (Ottawa, Ont., Canada) has a unique device and software solution to one of the most persistent problems in clinical trials: noncompliance. Its Med-ic ECM (Electronic Compliance Monitor) can be used with any blister package to track medication use without active patient input.
Med-ic ECM
The device uses sensor grid technology and a proprietary process of printed conductive inks to form a smart label that automatically tracks whether or not a patient takes medication. Med-ic ECM records the time each pill is expelled from the blister package, creating a record for analysis by clinical trial monitors.
The device's Med-ic ECM CertiScan RF Reader and CertiScan Compliance Monitoring Software capture and display patient compliance data with the latest RFID technology. The compliance monitoring system is disposable and features the technical controls to support 21 CFR Part 11 compliance without active input by the trial monitor.
Information Mediary Corporation, (613) 745-8400, www.med-ic.biz
Software delivers seamless supply chain management that integrates with third-party systems
ClinChain, Inc. (New Castle, DE) has found a way to help clinical supply professionals carry out all of their critical tasks with the click of a mouse. Version 3.2 of its ClinChain Plenish software package is a fully validated, 21 CFR Part 11-compliant software system that enables material receipts, manufacturing and primary and secondary packaging requests, site distributions, drug returns, and destructions.
ClinChain Plenish V. 3.2
At the heart of ClinChain Plenish are sophisticated data inheritance rules and inter-related drop-down menus that minimize user input and preserve data integrity. The software includes enterprise features such as multi-user client/server architecture, a robust reporting tool, broad genealogy tracking, and flexible data querying capabilities. It also integrates with other databases and third-party software standardized databases.
ClinChain, Inc., (302) 326-1342, www.clinchain.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.